Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study
Background Immunotherapies targeting programmed cell death-1 (PD-1) and its ligands have improved clinical outcomes for advanced melanoma. However, many tumors exhibit primary resistance or acquire secondary resistance after an initial positive response. The mechanisms of resistance are not well und...
Príomhchruthaitheoirí: | , , , , , , , , , , |
---|---|
Formáid: | Alt |
Teanga: | English |
Foilsithe / Cruthaithe: |
BMJ Publishing Group
2022-07-01
|
Sraith: | Journal for ImmunoTherapy of Cancer |
Rochtain ar líne: | https://jitc.bmj.com/content/10/7/e004879.full |